Despite this, it is advertised as a specific inhibitor and has been used to identify Rac1 as a new therapeutic target for the influenza virus, and in gefitinib‐resistant non‐small cell lung cancer.126 It has also been reported that NSC23766 acts as a competitive antagonist at muscarinic acetylcholine127 and NMDA128 receptors in a Rac1‐independent manner, at the same concentrations used for Rac1 inhibition. Here, RAC1 is linked to lung cancer.